This discrepancy, coupled with observations that Vangl2 is aberrantly expressed across diverse subtypes of invasive breast tumors [31], suggests that Wnt/PCP signaling may be a marker that could be used clinically to predict invasive or aggressive breast cancer. This evidence concerns the gene VANGL2 and breast cancer.